Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S1473-3099(20)30588-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Nigerian medicinal plants with potential anticancer activity-a review.
Explor Target Antitumor Ther
December 2024
Center for Natural Products Discovery (CNPD), School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool L3 3AF, UK.
Despite the fact that life expectancies are increasing and the burden of infectious diseases is decreasing, global cancer incidence rates are on the rise. Cancer outcome metrics are dismal for low- and middle-income countries (LMICs), including sub-Saharan Africa, where adequate resources and infrastructure for cancer care and control are lacking. Nigeria, the most populous country in Africa, exemplifies the miserable situation.
View Article and Find Full Text PDFPeptide therapeutics, a major class of medicines, have achieved remarkable success across diseases such as diabetes and cancer, with landmark examples such as GLP-1 receptor agonists revolutionizing the treatment of type-2 diabetes and obesity. Despite their success, designing peptides that satisfy multiple conflicting objectives, such as target binding affinity, solubility, and membrane permeability, remains a major challenge. Classical drug development and structure-based design are ineffective for such tasks, as they fail to optimize global functional properties critical for therapeutic efficacy.
View Article and Find Full Text PDFRobotic Resection of an Ectopic Parathyroid Gland: A Systematic Review.
Cureus
December 2024
General Surgery, East Sussex Healthcare NHS Trust, Brighton and Hove, GBR.
Ectopic parathyroid glands result from abnormal migration during development. If not detected promptly, they can lead to persistent or recurrent primary hyperparathyroidism (pHPT). Inferior parathyroid glands are typically located in the anterior mediastinum, while superior parathyroid glands are often near the tracheoesophageal groove, both of which contribute to pHPT.
View Article and Find Full Text PDFEfficacy and safety of immune checkpoint inhibitors for EGFR mutated non-small cell lung cancer: a network meta-analysis.
Front Immunol
January 2025
Wuhan Wuchang Hospital, Wuchang Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, China.
Introduction: Non-small cell lung cancer (NSCLC) constitutes approximately 80-85% of cancer-related fatalities globally, and direct and indirect comparisons of various therapies for NSCLC are lacking. In this study, we aimed to compare the efficacy and safety of immune checkpoint inhibitors (ICIs) in patients with epidermal growth factor receptor (EGFR)-mutated NSCLC.
Methods: The electronic databases were systematically searched from inception until March 18, 2024.
Background: The addition of durvalumab or pembrolizumab to gemcitabine and cisplatin (GP) has been approved to statistically improve survival outcomes in patients with advanced biliary tract cancer. However, since the survival time was only prolonged by about two months, doubts have been raised. In this analysis, we aimed to evaluate the efficacy of combining durvalumab or pembrolizumab with GP chemotherapy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!